At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: What bold models are emerging? We cover benefit design, PBMs, AI, evolving pharmacy models, and whether markets can act before regulation.

• Conference Overview
• Sarah Emond – ICER
• John O’Brien – National Pharmaceutical Council
• Annette Powers – Bristol Myers Squibb
• Ray Pressburger – Accenture

• Stuart Altman – Power, Politics and Universal Health Care
• PBMs
• 340B Program
• Copay Maximizers
• Net Price
• Lilly Direct
• Indolent Disease, PFS
• Concomitant Drug
• HIV & AZT
• Orphan Drugs
• Calquence vs Imbruvica
• Value-Based Contracts
• Outcome-Based Contracts
• Disruptive PBMs
• CostPlus Drugs
• Fair Access 2024
• Drug Rebates
• Drug Carve-Outs
• Dynamic Pricing
• Accelerated Approvals
• ICER Assessment

Questions? Email comments@prescriptionforbetteraccess.com.
Follow us on X, LinkedIn, YouTube, and Threads.

Specialty drug benefit design isn't just one decision — it triggers a domino effect impacting employer and health plan costs, patient access, care delivery and patient cost-sharing. In this episode, we unpack PSG’s latest research on how employers and health plans are rethinking specialty strategies amid rising pressure: cost management as a top priority, movement toward rebate alternatives, shifting site of care models, and evolving approaches to affordability and utilization management. Our guests break down where the biggest shifts are happening, what’s still missing, and how smarter benefit design can create better outcomes across the healthcare system.

• PSG (Pharmaceutical Strategies Group)
• 2025 Trends in Specialty Drug Benefits Report
• Specialty Drugs
• Drug Utilization
• PBM (Pharmacy Benefit Manager)
• Copay Assistance (Maximizers & Accumulators)
• Drug Rebates
• Drug “Carve Outs”
• Value-Based Agreements
• Utilization Management
• Step Therapy
• Biosimilars
• Site-of-Care

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

In this episode, we interview Brian Reid, the founder of Reid Strategic and the creator and editor of our favorite industry newsletter, the Cost Curve. Brian shares his journey to create the Cost Curve and how he navigates the onslaught of information to identify the most important issues of the day. We also get his take on what he calls the highest “importance-to-attention” healthcare stories, highlighting critical topics that are undercovered related to their significance. We also get the opportunity to understand his perspectives on the threats to innovation, the risks to patient affordability programs, and what all of us should be doing to be better healthcare consumers.

• Brian Reid- Reid Strategic
• Cost Curve Newsletter
• Martin Shkreli & Daraprim
• BioPharma Dive: Biotech and Pharma Industry News
• GLP-1s
• Net Price– “a drug’s net price equals the actual revenues that a manufacturer earns from a drug after rebates, discounts, and other reductions” Source: Drug Channels
• Armamentarium
• Pharmacy Benefit Managers (PBMs)
• Mark Cuban Pharmacy
• Psuedo-Generic Medication
• CVS Cordavis
• Quallent
• Nuvalia
• Biosimilars
• Lilly Direct
• Novo

• 340B Drug Pricing Program

• Copay maximizers
• AFPs

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.